
1. Technology overview
Anaconda Biomed is a medical technology company based in Sant Quirze del Valles, Barcelona, Spain (Carrer d'Eivissa 56), with a US presence in Marin, California. It develops thrombectomy catheters for ischemic stroke and other neurovascular disease.
The ANA5 is a sterile, single-use, self-expanding funnel catheter for mechanical thrombectomy. Its funnel-shaped tip combines aspiration with flow-arrest and flow-reversal to capture clots and limit embolic complications. The company reports CE Mark certification for ANA5 (announced June 2025) and notes the device is investigational in the United States while a randomized 327-subject pivotal study (ATHENA) proceeds.
2. Highlighted features & specifications
- Funnel geometry: self-expanding funnel tip designed to capture clots.
- Combined mechanism: aspiration with flow-arrest and flow-reversal.
- Size range: ANA5, ANA6 and ANA8 catheters.
- Conda stent retriever: complementary device in the portfolio.
- Single use: sterile, disposable catheter.
- Evidence: ATHENA randomized pivotal study of 327 subjects.
3. Potential application
Neurointerventional departments at Vietnamese stroke centers can evaluate the catheter for large vessel occlusion thrombectomy. Distributors of neurovascular devices can add it to portfolios where CE marking is accepted. Hospitals can use it in stroke-network training programs.
4. Benefits
Aims to maximize clot capture and improve first-pass recanalization in stroke thrombectomy. Combines aspiration with flow-arrest and flow-reversal to reduce embolic complications. Single-use sterile device with CE Mark for commercial distribution in Europe. Part of a growing portfolio of ANA5, ANA6, ANA8 and a stent retriever.
5. Market trends & opportunities
Mechanical thrombectomy is growing as stroke centers expand; the company cites about 270,000 procedures worldwide in 2026. Southeast Asian hospitals building comprehensive stroke programs, including in Vietnam, increasingly need neurointerventional devices.
6. Other information
Headquarters and production near Barcelona; US presence in Marin, California. September 2026 financing led by Omega Funds with FOCO, Asabys, Ysios Capital and CDTI. First US ATHENA patient enrolled April 2025. Listed among EIC Scaling Club healthtech scaleups by third-party coverage; EIC not stated on the vendor site.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































